Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Dexmedetomidine prevents acute kidney injury after adult cardiac surgery: a meta-analysis of randomized controlled trials

BMC AnesthesiologyBMC series – open, inclusive and trusted201818:7

https://doi.org/10.1186/s12871-018-0472-1

  • Received: 9 August 2017
  • Accepted: 4 January 2018
  • Published:
Open Peer Review reports

Abstract

Background

Dexmedetomidine has been shown to confer direct renoprotection by stabilizing the sympathetic system, exerting anti-inflammatory effects and attenuating ischemia/reperfusion (I/R) injury in preclinical studies. Results from clinical trials of dexmedetomidine on acute kidney injury (AKI) following adult cardiac surgery are controversial.

Methods

We searched EMBASE, PubMed, and Cochrane CENTRAL databases for randomized controlled trials (RCTs) comparing the renal effect of dexmedetomidine versus placebo or other anesthetic drugs in adult patients undergoing cardiac surgery. The primary outcome was the incidence of AKI. The secondary outcomes were mechanical ventilation (MV) duration, intensive care unit (ICU) stay and hospital length of stay(LOS), and postoperative mortality (in-hospital or within 30 days).

Results

Ten trials with a total of 1575 study patients were selected. Compared with controls, dexmedetomidine significantly reduced the incidence of postoperative AKI [68/788 vs 97/787; odds ratio(OR), 0.65; 95% confidence interval (CI), 0.45–0.92; P = 0.02; I2 = 0.0%], and there was no difference between groups in postoperative mortality (4/487 vs 11/483; OR, 0.43; 95% CI, 0.14–1.28; P = 0.13; I2 = 0.0%), MV duration [in days; n = 1229; weighted mean difference(WMD), −0.22; 95% CI, −2.04 to 1.70; P = 0.81], ICU stay (in days; n = 1363; WMD, −0.85; 95% CI, −2.14 to 0.45; P = 0.20), and hospital LOS (in days; n = 878; WMD, −0.24; 95% CI, −0.71 to 0.23; P = 0.32).

Conclusions

Perioperative administration of dexmedetomidine in adult patients undergoing cardiac surgery may reduce the incidence of postoperative AKI. Future trials are needed to determine the dose and timing of dexmedetomidine in improving outcomes, especially in patients with decreased baseline kidney function.

Keywords

  • Dexmedetomidine
  • Acute kidney injury
  • Cardiac surgery
  • Meta-analysis

Background

Acute kidney injury (AKI) following cardiac surgery is a widely recognized complication in association with high mortality risk [1, 2]. AKI is tightly interrelated with hemodynamic status, inflammatory and nephrotoxic components [3]. Both hemodynamic instability and sympathetic activity during surgery are harmful for renal function [4].Almost half of these patients need mechanical ventilation(MV) support and are related with prolonged intensive care unit (ICU) stay [5, 6].Moreover, along with the increasing high-risk population including advanced age, diabetes mellitus, severe cardiac failure, especially in association with cardiopulmonary bypass, AKI after cardiac surgery has become an interesting and challenge issue in clinical practice [7]. As yet, there is no definite strategy for preventing AKI after cardiac surgery [8].

Dexmedetomidine, a highly selective α2 adrenoreceptor agonist, induces sedation, analgesia, hemodynamic stabilization, anti-inflammation, as well as diuresis [9], and has theoretical advantage for reducing renal injury in animal studies [10, 11]. Several single-center randomized controlled trials (RCTs) with relatively small sample size have addressed this question and the results are controversial [1214]. Whether perioperative dexmedetomidine could reduce the risk for AKI in adult patients undergoing cardiac surgery remains unclear. In addition, there has been no systematic review that comprehensively focuses on the potential renal effect of dexmedetomidine in adult cardiac surgery. Therefore, we conducted a meta-analysis to evaluate the effect of perioperative dexmedetomidine (compared to placebo or other drugs) on the risk for AKI and mortality.

Methods

Search strategy and study criteria

This meta-analysis was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- analyses) guidelines [15] and approved by the Institutional Review Board in Beijing Shijitan Hospital, Capital Medical University. We did a systematic search in PubMed (1999 to March 2017), EMBASE (1999 to March 2017), and Cochrane Library (1999 to March 2017) using the keywords “dexmedetomidine,” “cardiac surgery,” “heart surgery,” “kidney,” and “renal.” English-published RCTs concerning adult patients were included. Exclusion criteria were as follows: emergency surgery, or studies without reporting AKI incidence.

Literature review and data extraction

The literature review and data extraction were independently completed by 2 investigators (BS and SZW). In case of duplicate records pertaining to a single study, we considered the PubMed database to take precedence. Disagreements were handled by discussion for consensus. Quality assessment was completed using the Cochrane risk of bias tool and Jadad scale. Data extraction included patient characteristics (age, proportion of males, proportion with diabetes, proportion with history of myocardial infarction, proportion with hypertension, baseline left ventricular ejection fraction, baseline creatinine levels, β-blocker use, and statin use), as well as dexmedetomidine dosage.

Postoperative outcomes

The primary end point was incidence of AKI (defined as RIFLE, AKIN, KDIGO within 7 days after cardiac surgery). Secondary outcomes included all-cause mortality (in-hospital or within 30 days), mechanical ventilation(MV) duration, ICU length of stay, and hospital length of stay(LOS).

Statistical analysis

For dichotomous outcomes (reported with incidence), we calculated the odds ratio (OR) with 95% confidence interval (CI). For continuous outcomes (reported as mean ± standard deviation, median and interquartile range, or median and range), we calculated mean differences for each study according to the statistical method of Hozo et al. [16] and used weight (the inverse variance of the estimate) to pool the estimate (weighted mean difference, WMD) with 95% CI. We used the random-effect model to pool all the data for the potential clinical inconsistency. Heterogeneity was assessed with the inconsistency statistic (I2). Publication bias was assessed by Begg’s test and Egger’s test. P < 0.05 (2 sided) was considered to be statistically significant for hypothesis testing. All statistical analyses were performed in REVMAN (version 5.0; Cochrane Collaboration, Oxford, UK) and Stata (version 9.0; StataCorp LP).

Results

Study characteristics

Figure 1 shows the PRISMA flow chart for the RCTs screening and selection process for inclusion in this study. Ten trials enrolling 1575 study subjects ultimately met our criteria (Fig. 1). Two studies were for coronary artery bypass grafting(CABG) [17, 19], seven were for combined cardiac surgery [1214, 18, 2022] and 1 was for aortic vascular surgery [23]. Six trials used placebo as control [12, 14, 17, 19, 22, 23], whereas two used propofol [18, 20], one used morphine [21] or remifentanil [13]. Dexmedetomidine was continuously infused at a rate of 0.2 to 0.8μg/kg/h for 24 h after a loading dose (0.4-1μg/kg) in 4 studies [13, 18, 22, 23] or infused at a rate of 0.04 to 1.5μg/kg/h without a loading dose in 6 [12, 14, 17, 1921].
Fig. 1
Fig. 1

Flow diagram of studies included into meta-analysis

For postoperative outcomes, AKI incidence was reported in 9 trials [1214, 17, 1923], need for dialysis in 1 [18], mortality in 6 [12, 18, 2023], mechanical ventilation duration in 8 [13, 14, 1722], ICU stay in 8 [1214, 17, 18, 2022], and hospital stay in 6 [13, 17, 18, 2022].

Study design and patient characteristics were summarized in Tables 1 and 2. The quality assessment was listed in Table 3.
Table 1

Summarized Study Design of Included Randomized Trials

Study

Country

Surgery

Dexmedetomidine Dose

Control

Time and Duration of intervention or Control

No. of Patients

Clinical End Point

AKI Definition

Follow-Up

Balkanay2015 I [17]

Turkey

On-PUMP CABG

0.04μg/kg/h-0.05μg/kg/h

placebo

Start preCPB and last for 24 h

31 vs 28

AKI;MV duration; ICU stay; Hospital stay

RIFLE

In hospital

Balkanay2015II [17]

Turkey

On-PUMP CABG

0.04μg/kg/h-0.05μg/kg/h

placebo

Start preCPB and last for 24 h

29 vs 28

AKI;MV duration; ICU stay; Hospital stay

RIFLE

In hospital

Cho 2015 [12]

Korea

Combined

0.04μg/kg/h

placebo

Start immediately after anesthetic induction and last for 24 h

100 vs100

AKI; Mortality; ICU stay;

AKIN

In hospital

DjaianiG 2016 [18]

Canada

Combined

0.4μg/kg 0.2–0.7μg/kg/h

propofol

Start postsurgery and last for 24 h

91 vs 92

AKI; Mortality; MV duration; ICU stay; Hospital stay

NA

In hospital

Leino 2011 [19]

Finland

On-PUMP CABG

0.6 ng/ml

placebo

Start immediately after anesthetic induction and last for 4 h arrive ICU

35 VS 31

AKI; MV duration;

RIFLE

In hospital

Li 2017 [14]

China

Combined

0.1μg/kg/h-0.6μg/kg/h

placebo

Start preCPB and last until the end of MV

142 vs143

AKI;MV duration; ICU stay

KDIGO

30 days after surgery

Liu 2016 [20]

China

Combined

<1.5μg/kg/h

propofol

Start after surgery and last until the end of MV

44 vs 44

AKI; Mortality; MV duration; ICU stay; Hospital stay

AKIN

In hospital

Park 2014 [13]

Korea

Combined

0.5μg/kg 0.2–0.8μg/kg/h

remifentanil

Start after surgery and last until extubation

67 vs 75

AKI; MV duration; ICU stay; Hospital stay

Cr > 100%abovebaseline or new dialysis need

In hospital

Shehabi2009 [21]

Australia

Combined

0.1–0.7μg/kg/ml

morphine

Start within 1 h of adminssin to CICU until the removal of chest drains

152 vs147

AKI; Mortality; MV duration; ICU stay; Hospital stay

NA

12 days after surgery

Ammar 2016 [22]

Egypt

Combined

1 μg/kg over 15 min, followed by 0.5 μg/kg/h

placebo

Start preCPB and last until 6 h after surgery

25 vs 25

AKI; Mortality; MV duration; ICU stay; Hospital stay

NA

30 days after surgery

Soliman 2016 [23]

Egypt

Aortic vascular surgery

1 μg/kg 0.3 μg/kg/h

placebo

Start 15 min before induction maintained to the end of surgery

75 vs 75

AKI; Mortality;

Cr > 115 μmol/L

In hospital

Abbreviations: AKI Acute kidney injury, CABG Coronary artery bypass graft, CPB Cardiopulmonary bypass, ICU Intensive care unit, CICU Cardiac intensive care unit, MV Mechanical ventilation, NA Not available, Cr Creatinine, RIFLE Risk–Injury–Failure–Loss–End-stage renal disease, AKIN Acute Kidney Injury Network, KDIGO Kidney Disease Improving Global Outcomes

Table 2

Summarized patient characteristic of the included randomized trials

Study

Age

Male (%)

DM (%)

HP (%)

PreMI (%)

LVEF (%)

CPB duration (min)

Anesthetics

Baseline Serum Creatinine

β-blocker (%)

Statins (%)

Balkanay 2015 I [17]

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Balkanay 2015II [17]

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Cho 2015 [12]

63

48

19.5

45.5

NA

61.5

131

Sevoflurane

33

NA

63

DjaianiG 2016 [18]

72.55

75.4

21.9

75.4

16.4

NA

98.99

Isoflurane

53

68.85

72.55

Leino 2011 [19]

60.86

89.4

NA

NA

NA

NA

NA

Isoflurane

NA

NA

60.86

Li 2017 [14]

67.18

69.1

32.3

63.2

9.8

NA

102.99

Sevoflurane

69.73

48.42

67.18

Liu 2016 [20]

54.75

39.8

12.5

29.5

NA

65

71.15

Sevoflurane

NA

NA

54.75

Park 2014 [13]

53.81

55.6

9.15

27.5

NA

61.87

166.75

Sevoflurane

NA

NA

53.81

Shehabi2009 [21]

71.25

75.3

29.5

80.1

36.6

NA

98.98

Sevoflurane

NA

NA

71.25

Ammar 2016 [22]

57.25

76

68

82

NA

NA

66.2

Isoflurane

94

56

57.25

Soliman 2016 [23]

58.1

50

30.7

48.7

8.6

52.9

NA

NA

36.67

NA

58.1

Abbreviations: DM Diabetes mellitus, HP Hypertension, PreMI Previous myocardial infarction, LVEF Left ventricular ejection fraction, CPB Cardiopulmonary bypass, NA Not available

Values are given as means unless otherwise specified

Table 3

Summarized Quality Assessment of Included Randomized Trials

Study

Random sequence generation

Allocation Concealment

Blinding of participants and personnel

Blinding of outcome assessment

Attrition bias

Selective reporting

Jadad scale

Balkanay 2015 I [17]

Yes

Unclear

Yes

Yes

Unclear

Unclear

4

Balkanay 2015 II [17]

Yes

Unclear

Yes

Yes

Unclear

Unclear

4

Cho 2015 [12]

Yes

Sealed envelopes

Blinding of personnel

Yes

Unclear

Unclear

4

Djaiani G 2016 [18]

Yes

Sealed envelopes

Blinding of personnel

No

Yes

Unclear

3

Leino 2011 [19]

Yes

Sealed envelopes

No

Yes

Yes

Unclear

5

Li 2017 [14]

Yes

Sealed envelopes

Yes

No

Yes

Unclear

5

Liu 2016 [20]

Yes

Unclear

Unclear

Unclear

Unclear

Unclear personnel

1

Park 2014 [13]

Yes

Unclear

Unclear

Unclear

Unclear

Unclear

1

Shehabi 2009 [21]

2009

Yes

Unclear

Yes

No

Yes

Unclear

5

Ammar 2016 [22]

Yes

Unclear

Yes

Yes

Unclear

Unclear

4

Soliman 2016 [23]

Yes

Unclear

Yes

No

Unclear

Unclear

4

Effect of Dexmedetomidine on incidence of AKI, and mortality

The outcome of AKI was reported in 1575 study participants, and the overall incidence was 10.48% (dexmedetomidine group, 68/788; control group, 97/787). The postoperative incidence of AKI was significantly reduced by dexmedetomidine (10 studies with 11 comparision; OR, 0.65; 95% CI, 0.45–0.92; P = 0.02; I2 = 0.0%; Fig. 2). Different analysis method (Mantel-Haenszel or Inverse Variance) or different summary statistics (RR vs OR vs RD) was listed in Table 4.There was no evidence of significant publication bias (Begg’s test, P = 0.22; Egger’s test, P = 0.32; Fig. 3).
Fig. 2
Fig. 2

Dexmedetomidine (Dex) reduced the incidence of acute kidney injury

Table 4

Different analysis method and summary statistics for the incidence of acute kidney injury

Analysis method

OR

95%CI

I2

P

RD

95%CI

I2

P

RR

95%CI

I2

P

Mantel-Haenszel

0.65

0.45,0.92

0%

0.02

−0.02

−0.04,0.01

46%

0.28

0.72

0.54,0.95

0%

0.02

Inverse Variance

0.65

0.45,0.92

0%

0.02

−0.01

−0.04,0.01

21%

0.22

0.72

0.54,0.95

0%

0.02

Abbreviations: OR Odds ratio, RR Risk ratio, RD Risk difference, CI Confidence interval

Fig. 3
Fig. 3

Funnel plot assessment of potential publication bias

Subgroup analyses for the potential sources of heterogeneity were listed in Table 5. We divided study participants into 11 groups according to different characteristics such as age(year, ≥60 versus <60), proportion of male (≥60% versus <60%), proportion with diabetes (≥25% versus <25%), CPB duration(min, ≥100 versus <100), statin use(≥60% versus <60%), loading dose (use or not), continuous infusion dosing (low versus high), controlled type (placebo versus nonplacebo), administration timing (pre/intraoperative versus postoperative), surgical type (CABG only versus combined) surgery, JADAD score (≥3 versus <3). Overall, no significant differences existed in the incidence of AKI (Table 5).
Table 5

Subgroup analyses for the potential sources of heterogeneity

Subgroup

Endpoint

No. of Comparisons

OR WMD

95% CI

P Value

I2

PDifference Value

1. Age(years)

AKI

9

0.64

0.41~ 1.01

0.06

43.8%

0.18

  ≥ 60

 

5

0.54

0.31~ 0.94

0.03

32%

 

  < 60

 

4

1.12

0.45~ 2.79

0.81

0%

 

2. Gender(Male%)

AKI

9

0.64

0.41~ 1.01

0.06

0%

0.91

  ≥ 60

 

4

0.70

0.28~ 1.74

0.45

47%

 

  < 60

 

5

0.75

0.46~ 1.20

0.22

0.0%

 

3. Previous DM (%)

AKI

8

0.64

0.41 ~ 1.01

0.22

0%

0.86

  ≥ 25

 

4

0.75

0.48 ~ 1.18

0.22

0%

 

  < 25

 

4

0.68

0.21 ~ 2.14

0.51

49%

 

4.CPB duration(minutes)

AKI

7

0.65

0.38 ~ 1.14

0.13

0%

0.59

  ≥ 100

 

3

0.61

0.27 ~ 1.36

0.22

60%

 

  < 100

 

4

0.85

0.34 ~ 2.15

0.73

0%

 

5.Statin (%)

AKI

9

0.64

0.41 ~ 1.01

0.06

43.8%

0.18

  ≥ 60

 

5

0.54

0.31~ 0.94

0.03

32%

 

  < 60

 

4

1.12

0.45 ~ 2.79

0.81

0%

 

6.Loading dose use

AKI

10

0.65

0.45 ~ 0.92

0.02

0%

0.86

 Yes

 

4

0.72

0.24 ~ 2.10

0.54

0%

 

 No

 

6

0.64

0.40 ~ 1.02

0.06

16%

 

7. Continuous infusion

AKI

9

0.61

0.42 ~ 0.88

0.008

68.3%

0.08

  ≥ 0.1 μg/kg/h

 

6

0.76

0.49~ 1.18

0.22

0%

 

  < 0.1 μg/kg/h

 

3

0.37

0.19 ~ 0.72

0.003

0%

 

8. Control drugs

AKI

11

0.65

0.45 ~ 0.92

0.02

0%

0.33

 Placebo

 

7

0.60

0.40 ~ 0.89

0.01

2%

 

 Others

 

4

0.96

0.40 ~ 2.29

0.93

0%

 

9. Dex administration

AKI

11

0.65

0.45 ~ 0.92

0.02

0%

0.21

 Pre/Intraoperation

 

8

0.59

0.40 ~ 0.87

0.007

0%

 

 Postoperation

 

3

1.11

0.45 ~ 2.74

0.83

0%

 

10. Surgical procedures

AKI

11

0.65

0.45 ~ 0.92

0.02

0%

0.87

 CABG or Aortic surgery

 

4

0.72

0.24 ~ 2.16

0.56

0%

 

 Combined

 

7

0.65

0.38 ~ 1.14

0.13

33%

 

11. JADAD score

AKI

11

0.65

0.45 ~ 0.92

0.02

65.7%

0.09

  ≥ 3

 

9

0.59

0.41 ~ 0.86

0.006

0%

 

  < 3

 

2

1.88

0.53 ~ 6.73

0.33

0%

 

Abbreviations: AKI Acute kidney injury, OR Odds ratio, CI Confidence interval, DM Diabetes mellitus, CPB Cardiopulmonary bypass, Dex Dexmedetomidine, CABG Coronary artery bypass graft

Sensitivity analysis excluding each included study at a time revealed that the Cho 2015 study was inconsistent with the direction and size of the overall AKI- reducing effect of dexmedetomidine (P = 0.34),and the other studies were consistent with the direction and size of the overall AKI- reducing effect of dexmedetomidine (P for all <0.04).

The outcome of mortality was reported in 970 study participants, and the overall incidence was 1.5% (dexmedetomidine group, 4/487; control group, 11/483). There were no statistically significant reduction for mortality owing to perioperative dexmedetomidine (6 studies; OR, 0.43; 95% CI, 0.14–1.28; P = 0.13; I2 = 0.0%; Fig. 4).
Fig. 4
Fig. 4

Forest plot for mortality

Effect of Dexmedetomidine on MV duration, ICU stay and hospital stay

A trend toward reduction of postoperative MV duration(8 studies WMD, −0.22; 95%CI, −2.04 to 1.70; P = 0.81; I2 = 68%; Fig. 5), ICU stay(8 studies; WMD, −0.85; 95%CI, −2.14 to 0.45; P = 0.20; I2 = 0%; Fig. 6) and hospital stay (6 studies; WMD, −0.24; 95%CI, −0.71 to 0.23; P = 0.32; I2 = 55%; Fig. 7) by dexmedetomidine was observed, although there were not statistically significant.
Fig. 5
Fig. 5

Forest plot for mechanical ventilation duration

Fig. 6
Fig. 6

Forest plot for intensive care unit stay

Fig. 7
Fig. 7

Forest plot for hospital length of stay

Discussion

In this meta-analysis of 10 RCTs involving 1575 adult patients undergoing cardiac surgery, we found that perioperative dexmedetomidine use was associated with a decrease in postoperative AKI risk. However, postoperative parameters including MV duration, ICU stay and hospital LOS appeared to be no significant decrease as a result of the dexmedetomidine use. To the best of our knowledge, this is the first meta-analysis evaluating the safety and efficacy of dexmedetomidine for the prevention of cardiac surgery associated AKI.

AKI is a common complication with an estimated incidence about 7% to 45% in adult cardiac surgery [24]. Small increases in postoperative serum creatinine levels after cardiac surgery have been reported to be associated with increased morbidity and mortality even if the renal function has returned to normal at discharge [25]. For this reason, strategies to lower the incidence of postoperative AKI are of high interest to clinicians.

Dexmedetomidine is widely used for perioperative anesthesia/analgesia, and may have a more profound renal protection by stabilizing the sympathetic system, exerting anti-inflammatory effects and attenuating ischemia/reperfusion (I/R) injury [10, 26]. In this meta-analysis, positive renoprotective effects were shown in 3 studies [12, 17, 22] and only 1 [12] study showed the prevention for the AKI. However, there were also controversial or negative studies pertaining to the effect of dexmedetomidine. Our analysis combining all these positive and negative studies showed a reduced incidence of AKI in association with the dexmedetomidine use. In view of the definition for AKI using conventional tests such as the blood urea nitrogen, serum creatinine levels, urine output quantity and creatinine clearance rate, it may result in delay in the timely detection of kidney injury and can lead to false-negative results, and dexmedetomidine for the prevention of AKI may be more effective than the current results.

In the included trials, dexmedetomidine was used with a loading dose (0.4μg/kg-1μg/kg) and continuous infusion (0.04–0.6μg/kg/h). Balkanay enrolled adult patients undergoing CABG found a significant difference between high dose group (8 μg/kg) and low dose group (4 μg/kg) for the 24th postoperative hour in the mean values of neutrophil gelatinase-associated lipocalin (NGAL) [17], indicating that dexmedetomidine had marked effects on renoprotection in a dose-dependent fashion. Our subgroup analyses showed that dexmedetomidine infusion without loading dose or at low continuous dose appeared to be safe and potentially efficacious by avoiding undesirable haemodynamic effects and was possibly more effective for renal-protection, although there was no significant difference (P = 0.86 and P = 0.08).To date, the optimal dose of dexmedetomidine to improve kidney function after cardiac surgery is unclear. The optimal dose of dexmedetomidine on postoperative renal events can’t be drew because of the lack of detailed patient data. Future large and well-designed randomized trails should explore the more appropriate dose of dexmedetomidine to maximize its renal protective effect with less side effects affecting prognosis.

The timing of dexmedetomidine administration in relation to cardiac surgery is emerging as an important consideration. In 6 of 10 included trials [12, 14, 17, 19, 22, 23], dexmedetomidine was used in a preemptive strategy, and early intervention of dexmedetomidine before the cardiopulmonary bypass seems to be critical for its organ-protective effect against I/R injury [27]. Dexmedetomidine pretreatment attenuated the I/R injury by reducing inflammatory response mediated by toll-like receptor4 expression [28, 29]. Our subgroup analyses indicated that dexmedetomidine was possibly more effective for renal-protection with pre/intraoperative administration compared with postoperative administration, but there was no significant difference (P = 0.21).Our findings do not provide a strong guidance on this question, and it merits further investigation. Future trials in this area would most likely be of greatest benefit.

Two recent expert consensus articles on postoperative AKI have been recently published, which discussed also new possible therapies/preventive measures [30, 31]. Our results was in keeping with one of the article conducted by M. Joannidis and colleagues, which showed dexmedetomidine was promising to reduce the rate of AKI, although no recommendation can be given on the basis of current data. Our subgroup analyses showed that dexmedetomidine was possibly effective for renal-protection compared with placebo but not against other treatments(P = 0.33). The advantages of dexmedetomidine compared with other anesthetics still call for further research.

Our analysis has several disadvantages. First, AKI in cardiac surgery is common and may have several different causes. It is difficult to establish a protective role for dexmedetomidine. We were unable to access individual patient data, so the influences of age, sex, and other confounding factors may be underestimated. Second, the definition of AKI was not uniform in the included trials. Third, sample size in each study is relatively low, so future large clinical studies were needed. Fourth, the exclusion of non-English studies may be inappropriate, however, the assessment of publication bias did not show statistical significance. Fifth, Bland [32] and Kwon & Reis [33] have argued that the statistical method of Hozo et al. may have limited their statistical ability to detect differences. When samples are not normally distributed. So the effect of dexmedetomidine may be overestimation, especially for negative findings. Last, perioperative dexmedetomidine might be of most benefit for certain patients who are at different stage of AKI, but most of the included study did not report the existed renal impairment before surgery.

Conclusion

In summary, available evidence from the present meta-analysis suggests that perioperative administration of dexmedetomidine in adult cardiac surgery might reduce the incidence of AKI. Future trials are needed to be much larger and ascertain the optimal dose and, more importantly, the time of the dose, especially in patients with decreased kidney function at baseline.

Abbreviations

AKI: 

Acute kidney injury

AKIN: 

Acute Kidney Injury Network

CI: 

Confidence interval

I/R: 

Ischemia/reperfusion

ICU: 

Intensive care unit

KDIGO: 

Kidney Disease Improving Global Outcomes

OR: 

Odds ratio

PRISMA: 

Preferred Reporting Items for Systematic Review and Meta-Analysis

RCTs: 

Randomized controlled trials

RIFLE: 

Risk–Injury–Failure–Loss–End-stage renal disease

WMD: 

Weighted mean difference

Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by Beijing Shijitan Hospital Youth Funds (grant no. 2016-q08).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Study design: YL; data acquisition: BS and SZW; data analysis/interpretation: YL, FPL and JZ; supervision or mentorship: WC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. YL and WC take responsibility that this study has been reported honestly, accurately, and transparently. All authors approved the final manuscript.

Ethics approval and consent to participate

This meta-analysis was approved by the Institutional Review Board in Shijitan Hospital, Capital Medical University, Beijing.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Intensive care unit, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Haidian District, Beijing, 100038, China

References

  1. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1:19–32.View ArticlePubMedGoogle Scholar
  2. Ortega-Loubon C, Fernández-Molina M, Carrascal-Hinojal Y, Fulquet-Carreras E. Cardiac surgery-associated acute kidney injury. Ann Card Anaesth. 2016;19:687–98.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37:85–98.PubMedPubMed CentralGoogle Scholar
  4. O'Neal JB, Shaw AD, Billings FT 4th. Acute kidney injury following cardiac surgery: current understanding and future directions. Crit Care. 2016;20:187.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Stafford-Smith M, Podgoreanu M, Swaminathan M, et al. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis. 2005;45:519–30.View ArticlePubMedGoogle Scholar
  6. Elmistekawy E, McDonald B, Hudson C, et al. Clinical impact of mild acute kidney injury after cardiac surgery. Ann Thorac Surg. 2014;98:815–22.View ArticlePubMedGoogle Scholar
  7. Xu J, Jiang W, Fang Y, Teng J, Ding X. Management of Cardiac Surgery-Associated Acute Kidney Injury. Contrib Nephrol. 2016;187:131–42.PubMedGoogle Scholar
  8. Shin SR, Kim WH, Kim DJ, Shin IW, Sohn JT. Prediction and prevention of acute kidney injury after cardiac surgery. Biomed Res Int. 2016;2016:2985148.PubMedPubMed CentralGoogle Scholar
  9. Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31–9.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 2011;15:R153.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Tan F, Chen Y, Yuan D, Gong C, Li X, Zhou S. Dexmedetomidine protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats. Biomed Rep. 2015;3:365–70.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Cho JS, Shim JK, Soh S, Kim MK, Kwak YL. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 2016;89:693–700.View ArticlePubMedGoogle Scholar
  13. Park JB, Bang SH, Chee HK, Kim JS, Lee SA, Shin JK. Efficacy and safety of dexmedetomidine for postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg. 2014;47:249–54.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Li X, Yang J, Nie XL, et al. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: a randomized controlled trial. PLoS One. 2017;12:e0170757.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Moher D, Liberati A, Tetzlaff J, The ADG, PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13. https://doi.org/10.1186/1471-2288-5-13.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Balkanay OO, Goksedef D, Omeroglu SN, Ipek G. The dose-related effects of dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery bypass grafting: a randomized, triple-blind, placebo-controlled study. Interact Cardiovasc Thorac Surg. 2015;20:209–14.View ArticlePubMedGoogle Scholar
  18. Djaiani G, Silverton N, Fedorko L, et al. Dexmedetomidine versus Propofol sedation reduces delirium after cardiac surgery: a randomized controlled trial. Anesthesiology. 2016;124:362–8.View ArticlePubMedGoogle Scholar
  19. Leino K, Hynynen M, Jalonen J, Salmenperä M, Scheinin H, Aantaa R. Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study. BMC Anesthesiol. 2011;11:9.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Liu X, Zhang K, Wang W, Xie G, Fang X. Dexmedetomidine sedation reduces atrial fibrillation after cardiac surgery compared to propofol: a randomized controlled trial. Crit Care. 2016;20:298.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to morphine-DEXCOM study). Anesthesiology. 2009;111:1075–84.View ArticlePubMedGoogle Scholar
  22. Ammar AS, Mahmoud KM, Kasemy ZA, Helwa MA. Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: a randomized controlled trial. Saudi J Anaesth. 2016;10:395–401.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Soliman R, Zohry G. The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery. Ann Card Anaesth. 2016;19:606–13.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Lau G, Wald R, Sladen R, Mazer CD. Acute kidney injury in cardiac surgery and cardiac intensive care. Semin Cardiothorac Vasc Anesth. 2015;19:270–87.View ArticlePubMedGoogle Scholar
  25. Lassnigg A, Schmid ER, Hiesmayr M, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med. 2008;36:1129–37.View ArticlePubMedGoogle Scholar
  26. Ueki M, Kawasaki T, Habe K, Hamada K, Kawasaki C, Sata T. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia. 2014;69:693–700.View ArticlePubMedGoogle Scholar
  27. Zhang XY, Liu ZM, Wen SH, et al. Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats. Anesthesiology. 2012;116:1035–46.View ArticlePubMedGoogle Scholar
  28. Liu G, Song H, Qiu L, et al. Dexmedetomidine preconditioning inhibits the long term inflammation induced by renal ischemia/reperfusion injury in rats. Acta Cir Bras. 2016;31:8–14.View ArticlePubMedGoogle Scholar
  29. Lempiäinen J, Finckenberg P, Mervaala EE, et al. Dexmedetomidine preconditioning ameliorates kidney ischemia-reperfusion injury. Pharmacol Res Perspect. 2014;2:e0004.View ArticleGoogle Scholar
  30. Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43(6):730-49. https://doi.org/10.1007/s00134-017-4832-y.
  31. Bellomo R, Ronco C, Mehta RL, et al. Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference. Ann Intensive Care. 2017;7(1):49. https://doi.org/10.1186/s13613-017-0260-y.
  32. Bland M. Estimating mean and standard deviation from the sample size, three quartiles, minimum, and maximum. Int J Stat Med Res. 2015;4:57–64. https://doi.org/10.6000/1929-6029.2015.04.01.6.View ArticleGoogle Scholar
  33. Kwon D, Reis IM. Simulation-based estimation of mean and standard deviation for meta-analysis via approximate Bayesian computation (ABC). BMC Med Res Methodol. 2015;15:61. https://doi.org/10.1186/s12874-015-0055-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement